Veterinarians interested in OSURNIA should talk to their Elanco sales representative or call 1-877-352-6261 for information. *OSURNIA is indicated for the treatment of otitis externa in dogs ...

Osurnia and Capstar account for approximately half of that revenue. FRANK RUMPENHORST/AFP/Getty Images. By Lily Lieberman – Staff Writer, Kansas City Business Journal. Jan 13, 2020 ...

Elanco has made the independent decision to divest global rights to Osurnia, which had 2018 annual revenue of $31.2 million, with intent to advance the previously announced acquisition of Bayer ...

Osurnia had 2018 annual revenue of $31.2 million. Dechra Pharma expects the acquisition to be earnings enhancing for the financial year ending 30 June 2021. Ian Page, ...

(RTTNews) - The UK Competition and Markets Authority or CMA Monday said it has launched a merger inquiry into Dechra Pharmaceuticals PLC's (DPH.L) anticipated acquisition of the Osurnia business ...

The Board of Dechra is pleased to announce that it has agreed terms to acquire the worldwide rights to the Osurnia product portfolio (Osurnia) from Elanco Animal Health Incorporated (Elanco) for a ...

The Commerce Commission has granted clearance to Dechra Pharmaceuticals PLC, Dechra Limited and Dechra Veterinary Products LLC to acquire the assets, rights and liabilities relating to Osurnia ...

(Alliance News) - Dechra Pharmaceuticals PLC on Monday said it has bought worldwide rights for Osurnia, a treatment for inflammation of the outer ear in dogs, for USD135 million. The veterinary ...